Dejan Juric, MD
Hematology & Oncology · Boston, MANPI 1306041975
Payments from drug & device makers
Across 637 payments — averaging $15,681 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2.2M
- Genentech, Inc.$2M
- Novartis$1.9M
- Eli Lilly$1.3M
- AstraZeneca$970K
- Takeda Pharmaceuticals U.S.A., Inc.$839K
- plus $795K from 12 others
Across 57 payments — averaging $932.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$24K
- Novartis$19K
- Novartis Pharma AG$7K
- Pfizer$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 211 | $2,238,713 |
| Genentech, Inc. | 121 | $1,958,630 |
| Novartis | 86 | $1,926,179 |
| Eli Lilly | 11 | $1,261,183 |
| AstraZeneca | 13 | $970,179 |
| Takeda Pharmaceuticals U.S.A., Inc. | 56 | $838,700 |
| Blueprint Medicines Corporation | 77 | $489,221 |
| Verastem, Inc. | 3 | $71,026 |
| EMD Serono, Inc. | 3 | $52,814 |
| Sanofi US Services Inc. | 12 | $47,976 |
| F. Hoffmann-la Roche AG | 13 | $42,775 |
| Seagen Inc. | 4 | $41,800 |
| Novartis Pharma AG | 8 | $30,879 |
| Amgen | 5 | $10,840 |
| Eisai Inc. | 2 | $4,200 |
| Roche Products Limited | 10 | $3,375 |
| Astrazeneca UK Limited | 1 | $45 |
| Gilead | 1 | $12 |
How this compares
$9,988,546 in reported general payments places this provider in the 90th percentile of 374 hematology & oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Boston
- Matthew DavidsBoston$58.6M
- Nadine TungBoston$32.4M
- Jorge CastilloBoston$31.2M
- Daniel DeangeloBoston$28.5M
- Sara TolaneyBoston$20.3M
- Paul RichardsonBoston$17.2M
- Amir FathiBoston$14.8M
- Jacqueline GarciaBoston$13.6M
- John KorethBoston$12.8M
- David ReardonBoston$12M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.